



Gesundheits
Piazza
Bodensee

4

Heraeus

Pre-Conference: Health Economics

Gesundheits Piazza Bodensee

30–31 March 2011
Festspielhaus Bregenz



© Bruno Klotz

Agenda



Evaluation and Pricing of Health Technologies

Introduction

Some decision-makers and policy-makers claim, that if current trends continue, healthcare spending will leave governments bankrupt within decades.

As healthcare budgets are stretched, healthcare payers and reimbursement authorities support more complex health technology assessments.

Payers and providers need information about costs and health benefits to determine the best way of allocating scarce healthcare resources.

Increasingly reimbursement authorities require appropriate economic evidence along with data on safety and clinical effectiveness.

The goal is to ensure that a given population receives secure and economical healthcare. This evidence must be produced before a product can gain formulary approval or reimbursement.

Health economics examines how the costs and health benefits associated with innovative health technologies compare with standard management or a competitor treatment. Therefore it is becoming more and more important that the basic concepts of health economics are understood.





Program and Content (The schedule can be subject to change)

Day One: 30.03.2011

10:00–12:00

Overview – The Structure of a Health Economic Evaluation

- What is Health Economics?
- What are Economic Evaluations?
- How do people normally make decisions?
- Is the Perspective important?

Defining Costs in Health Economic Evaluations

- What do we mean by Cost?
- How is Costs Categorized?
- How do we Value Costs?

13:30–15:30

Defining Benefits in Health Economic Evaluations

- What are Benefits?
- What are Patient-Relevant or Intermediate Endpoints?
- What are Final Outcomes?
- What are Patient Reported Outcomes?
- How do we get Quality-Adjusted Life-Years?

Data Sources and Data Collection

- How do we Collecting Data?
- What are Prospective Data Sources?
- What are Retrospective Data Sources?
- What are Patient Registries?
- Are there other Data Sources?

16:00–18:00

Types of Economic Analyses

- What is Cost-Effectiveness Analysis?
- What is Cost-Consequence Analysis?
- What is Cost-Utility Analysis?
- What is Cost-Benefit Analysis?
- What is Cost-Minimization Analysis?
- What is Cost-of-Illness Study?
- What is Budget-Impact Analysis?

Day Two: 31.03.2011

10:00–12:00

Modeling and Decision Trees

- Why use Modeling in Health Technology Assessment?
- What is a Decision Tree?
- What Comprises a Model?

13:30–15:00

Why elicit Patient Preferences?

- How might Preference Research influence Health Technology Assessment?
- What are Conjoint Analysis and Discrete Choice Experiments?
- How can endpoints be identified and weighted?

16:00

(Workshop Gesundheitspiazza; Alric Rüter, Peter Kolominsky-Rabas)

Uses of Health Economics in Health Care Decision Making
Health Technology Assessment in Germany (Efficiency Frontiers)
Health Technology Assessment in GB (QALY)
Health Technology Assessment in USA (Comparative Effectiveness)



Speakers

Michael Drummond BSc, MCom, DPhil

is Professor of Health Economics and former Director of the Centre for Health Economics at the University of York. His particular field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunization programmes, services for people with AIDS, eye health care and pharmaceuticals. He is the author of two major textbooks and more than 600 scientific papers, has acted as a consultant to the World Health Organization and was Project Leader of a European Union Project on the Methodology of Economic Appraisal of Health Technology. He has been President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research. He is currently a member of the Guidelines Review Panels of the National Institute for Health and Clinical Excellence (NICE) in the UK, and is a Principal Consultant for i3Innovus. In 2008 he received an Honorary Doctor of Science from City University, London.

Dr. Peter L. Kolominsky-Rabas, M.D., Ph.D., MBA

Peter Kolominsky-Rabas, MD, PhD, MBA, is Director of the Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen-Nurnberg, Germany. In this function he coordinates since 2010 the HTA program within the Leading-Edge Cluster 'Centre of excellence for medical technology – Medical Valley EMN' in the Metropolitan Region Nurnberg. His research interests are in the field of health technology assessment, health economics, and outcomes research. Dr. Kolominsky-Rabas received his MD degree 'summa cum laude' from the University of Muenster and his PhD from the University of Erlangen in 2003. He received his MBA from the University of Bayreuth and is Senior Lecturer in Public Health and Outcomes Research since 2003. From 2005–2008 Dr. Kolominsky-Rabas was Head of Department 'Health Economics and Outcomes Research' in the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne, which is the main scientific advisory body to the Federal Government and the Federal Joint Committee (GBA) representing the German Statutory Health Insurance System. During this time Dr. Kolominsky-Rabas was deeply involved in shaping the HTA conception for the German health care system and all strategic matters. He established a world-wide advisory network including leading health economists and HTA agencies such as NICE (UK), HAS (France), Institute for Clinical Evaluative Sciences, (Canada) and LBI-HTA (Austria). Dr. Kolominsky-Rabas is advisor to several national health institutions in Germany as well as to governmental agencies in the European Union.

Prof. Dr. Axel Mühlbacher (Duke University, US)

Axel Mühlbacher, Dr. rer. oec., a 2010–11 Harkness Fellow in Health Care Policy and Practice placed at Duke Clinical Research Institute and Fuqua School of Business, Duke University. His research focuses on patient preferences, comparative effectiveness / economic evaluation methods and organized health care. Axel Mühlbacher is full professor and holder of the endowed foundation professorship of health economics and health care management at the Hochschule Neubrandenburg funded by the German statutory pension insurance (North). He also is an economist at the Centre of Innovative Health Technologies (ZIG), Technical University Berlin and a member at the Berlin School of Public Health, Charité Berlin. In 1996 he graduated from the Eberhard-Karls University, Tübingen, where he studied business administration and economics. In 1996 he was appointed as research fellow at the German Coordinating Agency of Public Health (GCAPH) at Albert-Ludwig University, Freiburg. In 1999 he joined the research training group „Demand-oriented and cost-effective Health Care – Fundamentals of optimal Allocation“ (Graduiertenkolleg) at TU Berlin, HU, FU Berlin with a Scholarship from the German Research Foundation (DFG). In 2001 he graduated with a doctorate in economics and business administration (Dr. rer. oec.) with a thesis on Management and organization of integrated care – an economic analysis of health care delivery networks (summa cum laude). Prior to founding the Institute of Health Economics and Health Care Management in 2006, Dr. Mühlbacher was assistant professor at the department of economics and management at Technical University Berlin (2001–2004) and associate professor of economics, health economics and econometrics (C2) at Hochschule Neubrandenburg (2004–2006).

www.heraeus-medical.com